Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation - Top-Institutions - MDSpire

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

  • By

  • Paola Facheris

  • Francesco Piscazzi

  • Giovanni Fiorillo

  • Mario Valenti

  • Antonio Costanzo

  • Riccardo G. Borroni

  • April 24, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Clinical Epidemiology

  • #3

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Medicine

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Health Outcomes Research

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Psoriasis Treatment

Original Source(s)

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

  • by Paola Facheris, Francesco Piscazzi, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Riccardo G. Borroni

  • April 24, 2026

Related Content

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies